ライター症候群治療の世界市場：薬剤タイプ別、剤形別、投与経路別、流通チャネル別、エンドユーザー別、地域別?業界規模、シェア、動向、競合、機会、予測、競合（2017年～2027年）

世界のライター症候群治療の市場規模は、予測期間（2023年～2027年）中に安定したCAGRで成長すると予測されています。

急速に増加する反応性関節炎、その効果的な治療に対する需要の高まり、医療業界の進歩は、市場の成長を促進しています。

当レポートでは、世界のライター症候群治療市場について調査分析し、製品概要、市場の展望、競合情勢など、体系的な情報を提供しています。

目次

第1章 製品概要

第2章 調査手法

第3章 COVID-19が世界のライター症候群治療市場に与える影響

第4章 エグゼクティブサマリー

第5章 VOC (顧客の声)

• 選好：薬剤タイプ別
• ライター症候群治療の需要が高まる要因
• ライター症候群治療の採用に対する障壁
• ブランド認知度

第6章 臨床試験

• 進行中の臨床試験
• 完了した臨床試験
• 中断した臨床試験
• 臨床試験分析

第7章 特許分析

• 特許取得済み（2016年～2020年）
• 特許出願

第8章 世界のライター症候群治療市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 薬剤タイプ別（抗生物質、コルチコステロイド、非ステロイド性抗炎症薬（NSAID）、免疫抑制薬、その他）
  • 剤形別（錠剤、注射剤、その他）
  • 投与経路別（経口、静脈内、その他）
  • 流通チャネル別（小売薬局、病院薬局、オンライン薬局）
  • エンドユーザー別（病院・クリニック、外来治療センター、その他）
  • 企業別（2021年）
  • 地域別
• 製品市場マップ

第9章 北米のライター症候群治療市場の展望

第10章 欧州のライター症候群治療市場の展望

第11章 アジア太平洋のライター症候群治療市場の展望

第12章 南米のライター症候群治療市場の展望

第13章 中東およびアフリカのライター症候群治療市場の展望

第14章 市場力学

• 促進要因
• 課題

第15章 市場の動向と開発

第16章 競合情勢

• F. Hoffmann-La Roche AG
• Pfizer, Inc.
• Novartis AG
• Cipla Inc.
• Dr. Reddy's Laboratories Ltd.
• Abbott Laboratories, Inc.
• GlaxoSmithKline plc
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Ltd
• AstraZeneca, Plc.

第17章 戦略的提言

第18章 当社について・免責事項

Global Reiter's syndrome treatment market is projected to register CAGR growth in the forecast years, 2023-2027 on the account of growth factors like increasing instances of reactive arthritis, along with the advancement of the treatment processes and methods. Moreover, advancing healthcare industry for the better availability of the patient care suffering from severe conditions like reactive arthritis, is also responsible for the growth of the global Reiter's syndrome treatment market in the upcoming five years.

Reiter's syndrome is also known as reactive arthritis, which is a form of inflammatory arthritis. It is the joint disease that causes painful inflammations. The disease is a reaction to a bacterial infection. These bacteria are often found in genitals like Chlamydia trachomatis or in bowel like Campylobacter, Salmonella, Shigella and Yersinia. Genital bacteria transmit through sex and usually does not show major symptoms. In certain cases, a pus-like or watery discharge from the genitals is observed. Whereas bowel bacteria usually cause diarrhea along with discharge and can be considered as minor symptoms of Reiter's syndrome.

Increasing Instances of Reiter's Syndrome Drives Market Growth

Rapidly increasing instances of reactive arthritis and surging demand for the effective treatment of the same in driving the growth of the global Reiter's syndrome treatment market in the upcoming five years. Reactive arthritis is a rare form of arthritis when compared to other forms of arthritis. More than 350 million patients of arthritis are currently suffering as of 2021 in the entire world. According to CDC, In the United States, 24% of all adults, or 58.5 million people, have arthritis. 1 in every 4 adults has arthritis and reports severe joint pain.

Whereas twenty-seven per 100,000 population globally suffers from Reiter's syndrome, that majorly affects the adult males between 20-40 years of age. Growing population, increasing instances of unprotected sexual intercourse, increase the chances of the population contracting the disease and thus aiding to the growth of the global Reiter's syndrome treatment market in the next five years.

Market Segmentation

The global Reiter's syndrome treatment market segmentation is based on drug type, dosage form, route of administration, distribution channel, end user, regional distribution, and competitive landscape. Drug type market segment is further fragmented into antibiotics, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), immunosuppressive drugs, and others. Based on dosage form, the market is sub-segmented into tablets, injections, and others. Market segmentation on the basis of route of administration, is further bifurcated into oral, intravenous, and others. Distribution channel segment is differentiated further among retail pharmacies, hospital pharmacies, and online pharmacies. The end user segment analysis the market fragments among hospitals & clinics, ambulatory care centers, and others. The market analysis also studies the regional segmentation, divided among Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.

Company Profile

F. Hoffmann-La Roche AG, Pfizer, Inc., Novartis AG, Cipla Inc., Dr. Reddy's Laboratories Ltd., Abbott Laboratories, Inc., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd, AstraZeneca, Plc., are enlisted in a partial list of major market players of the global Reiter's syndrome treatment market.

Report Scope:

In this report, global Reiter's syndrome treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Reiter's Syndrome Treatment Market, By Drug Type:

Antibiotics

Corticosteroids

Nonsteroidal anti-inflammatory drugs (NSAIDs)

Immunosuppressive Drugs

Others

• Reiter's Syndrome Treatment Market, By Dosage Form:

Tablets

Injections

Others

• Reiter's Syndrome Treatment Market, By Route of Administration:

Oral

Intravenous

Others

• Reiter's Syndrome Treatment Market, By Distribution Channel:

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

• Reiter's Syndrome Treatment Market, By End User:

Hospitals & Clinics

Ambulatory Care Centers

Others

• Reiter's Syndrome Treatment Market, By Region:

North America

• United States
• Mexico
• Canada

Europe

• France
• Germany
• United Kingdom
• Italy
• Spain

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE

South America

• Brazil
• Argentina
• Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Reiter's syndrome treatment market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Reiter's Syndrome Treatment Market

4. Executive Summary

5. Voice of Customer

• 5.1. Preference, By Drug Type
• 5.2. Factors Contributing to Higher Demand of Reiter's Syndrome Treatment
• 5.3. Barriers to Adoption of Reiter's Syndrome Treatment
• 5.4. Brand Awareness

6. Clinical Trials

• 6.1. Ongoing Clinical Trials
• 6.2. Completed Clinical Trials
• 6.3. Terminated Clinical Trials
• 6.4. Clinical Trial Analysis

7. Patent Analysis

• 7.1. Patent Granted (2016-2020)
• 7.2. Patent Applications Filed

8. Global Reiter's Syndrome Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type (Antibiotics, Corticosteroids, Nonsteroidal anti-inflammatory drugs (NSAIDs), Immunosuppressive Drugs, Others)
  • 8.2.2. By Dosage Form (Tablets, Injections, Others)
  • 8.2.3. By Route of Administration (Oral, Intravenous, Others)
  • 8.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
  • 8.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 8.2.6. By Company (2021)
  • 8.2.7. By Region
• 8.3. Product Market Map

9. North America Reiter's Syndrome Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Dosage Form
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. North America: Country Analysis
  • 9.3.1. United States Reiter's Syndrome Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Dosage Form
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
      • 9.3.1.2.5. By End User
  • 9.3.2. Mexico Reiter's Syndrome Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Dosage Form
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
      • 9.3.2.2.5. By End User
  • 9.3.3. Canada Reiter's Syndrome Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Dosage Form
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel
      • 9.3.3.2.5. By End User

10. Europe Reiter's Syndrome Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Dosage Form
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. Europe: Country Analysis
  • 10.3.1. France Reiter's Syndrome Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Dosage Form
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
      • 10.3.1.2.5. By End User
  • 10.3.2. Germany Reiter's Syndrome Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Dosage Form
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
      • 10.3.2.2.5. By End User
  • 10.3.3. United Kingdom Reiter's Syndrome Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Dosage Form
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel
      • 10.3.3.2.5. By End User
  • 10.3.4. Italy Reiter's Syndrome Treatment Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Drug Type
      • 10.3.4.2.2. By Dosage Form
      • 10.3.4.2.3. By Route of Administration
      • 10.3.4.2.4. By Distribution Channel
      • 10.3.4.2.5. By End User
  • 10.3.5. Spain Reiter's Syndrome Treatment Market Outlook
    • 10.3.5.1. Market Size & Forecast
      • 10.3.5.1.1. By Value
    • 10.3.5.2. Market Share & Forecast
      • 10.3.5.2.1. By Drug Type
      • 10.3.5.2.2. By Dosage Form
      • 10.3.5.2.3. By Route of Administration
      • 10.3.5.2.4. By Distribution Channel
      • 10.3.5.2.5. By End User

11. Asia-Pacific Reiter's Syndrome Treatment Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Drug Type
  • 11.2.2. By Dosage Form
  • 11.2.3. By Route of Administration
  • 11.2.4. By Distribution Channel
  • 11.2.5. By End User
  • 11.2.6. By Country
• 11.3. Asia-Pacific: Country Analysis
  • 11.3.1. China Reiter's Syndrome Treatment Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Drug Type
      • 11.3.1.2.2. By Dosage Form
      • 11.3.1.2.3. By Route of Administration
      • 11.3.1.2.4. By Distribution Channel
      • 11.3.1.2.5. By End User
  • 11.3.2. India Reiter's Syndrome Treatment Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Drug Type
      • 11.3.2.2.2. By Dosage Form
      • 11.3.2.2.3. By Route of Administration
      • 11.3.2.2.4. By Distribution Channel
      • 11.3.2.2.5. By End User
  • 11.3.3. South Korea Reiter's Syndrome Treatment Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Drug Type
      • 11.3.3.2.2. By Dosage Form
      • 11.3.3.2.3. By Route of Administration
      • 11.3.3.2.4. By Distribution Channel
      • 11.3.3.2.5. By End User
  • 11.3.4. Japan Reiter's Syndrome Treatment Market Outlook
    • 11.3.4.1. Market Size & Forecast
      • 11.3.4.1.1. By Value
    • 11.3.4.2. Market Share & Forecast
      • 11.3.4.2.1. By Drug Type
      • 11.3.4.2.2. By Dosage Form
      • 11.3.4.2.3. By Route of Administration
      • 11.3.4.2.4. By Distribution Channel
      • 11.3.4.2.5. By End User
  • 11.3.5. Australia Reiter's Syndrome Treatment Market Outlook
    • 11.3.5.1. Market Size & Forecast
      • 11.3.5.1.1. By Value
    • 11.3.5.2. Market Share & Forecast
      • 11.3.5.2.1. By Drug Type
      • 11.3.5.2.2. By Dosage Form
      • 11.3.5.2.3. By Route of Administration
      • 11.3.5.2.4. By Distribution Channel
      • 11.3.5.2.5. By End User

12. South America Reiter's Syndrome Treatment Market Outlook

• 12.1. Market Size & Forecast
  • 12.1.1. By Value
• 12.2. Market Share & Forecast
  • 12.2.1. By Drug Type
  • 12.2.2. By Dosage Form
  • 12.2.3. By Route of Administration
  • 12.2.4. By Distribution Channel
  • 12.2.5. By End User
  • 12.2.6. By Country
• 12.3. South America: Country Analysis
  • 12.3.1. Brazil Reiter's Syndrome Treatment Market Outlook
    • 12.3.1.1. Market Size & Forecast
      • 12.3.1.1.1. By Value
    • 12.3.1.2. Market Share & Forecast
      • 12.3.1.2.1. By Drug Type
      • 12.3.1.2.2. By Dosage Form
      • 12.3.1.2.3. By Route of Administration
      • 12.3.1.2.4. By Distribution Channel
      • 12.3.1.2.5. By End User
  • 12.3.2. Argentina Reiter's Syndrome Treatment Market Outlook
    • 12.3.2.1. Market Size & Forecast
      • 12.3.2.1.1. By Value
    • 12.3.2.2. Market Share & Forecast
      • 12.3.2.2.1. By Drug Type
      • 12.3.2.2.2. By Dosage Form
      • 12.3.2.2.3. By Route of Administration
      • 12.3.2.2.4. By Distribution Channel
      • 12.3.2.2.5. By End User
  • 12.3.3. Colombia Reiter's Syndrome Treatment Market Outlook
    • 12.3.3.1. Market Size & Forecast
      • 12.3.3.1.1. By Value
    • 12.3.3.2. Market Share & Forecast
      • 12.3.3.2.1. By Drug Type
      • 12.3.3.2.2. By Dosage Form
      • 12.3.3.2.3. By Route of Administration
      • 12.3.3.2.4. By Distribution Channel
      • 12.3.3.2.5. By End User

13. Middle East and Africa Reiter's Syndrome Treatment Market Outlook

• 13.1. Market Size & Forecast
  • 13.1.1. By Value
• 13.2. Market Share & Forecast
  • 13.2.1. By Drug Type
  • 13.2.2. By Dosage Form
  • 13.2.3. By Route of Administration
  • 13.2.4. By Distribution Channel
  • 13.2.5. By End User
  • 13.2.6. By Country
• 13.3. MEA: Country Analysis
  • 13.3.1. South Africa Reiter's Syndrome Treatment Market Outlook
    • 13.3.1.1. Market Size & Forecast
      • 13.3.1.1.1. By Value
    • 13.3.1.2. Market Share & Forecast
      • 13.3.1.2.1. By Drug Type
      • 13.3.1.2.2. By Dosage Form
      • 13.3.1.2.3. By Route of Administration
      • 13.3.1.2.4. By Distribution Channel
      • 13.3.1.2.5. By End User
  • 13.3.2. Saudi Arabia Reiter's Syndrome Treatment Market Outlook
    • 13.3.2.1. Market Size & Forecast
      • 13.3.2.1.1. By Value
    • 13.3.2.2. Market Share & Forecast
      • 13.3.2.2.1. By Drug Type
      • 13.3.2.2.2. By Dosage Form
      • 13.3.2.2.3. By Route of Administration
      • 13.3.2.2.4. By Distribution Channel
      • 13.3.2.2.5. By End User
  • 13.3.3. UAE Reiter's Syndrome Treatment Market Outlook
    • 13.3.3.1. Market Size & Forecast
      • 13.3.3.1.1. By Value
    • 13.3.3.2. Market Share & Forecast
      • 13.3.3.2.1. By Drug Type
      • 13.3.3.2.2. By Dosage Form
      • 13.3.3.2.3. By Route of Administration
      • 13.3.3.2.4. By Distribution Channel
      • 13.3.3.2.5. By End User

14. Market Dynamics

• 14.1. Drivers
• 14.2. Challenges

15. Market Trends & Developments

16. Competitive Landscape

• 16.1. F. Hoffmann-La Roche AG
• 16.2. Pfizer, Inc.
• 16.3. Novartis AG
• 16.4. Cipla Inc.
• 16.5. Dr. Reddy's Laboratories Ltd.
• 16.6. Abbott Laboratories, Inc.
• 16.7. GlaxoSmithKline plc
• 16.8. Sun Pharmaceutical Industries Ltd
• 16.9. Teva Pharmaceutical Industries Ltd
• 16.10. AstraZeneca, Plc.

17. Strategic Recommendations

18. About Us & Disclaimer